RxDoctor Payments Data

Shai Posner, MD

Gastroenterology · Albany, NYNPI 1295120863

Payments from drug & device makers

$318in general payments, 2019–2025

Across 10 payments — averaging $31.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$118
  • AbbVie$91
  • Takeda Pharmaceuticals U.S.A., Inc.$25
  • Ferring Pharmaceuticals Inc.$24
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$22
  • Bristol Myers Squibb$21
  • plus $18 from 1 others

What the payments were for

  • Speaking & faculty fees$206%
  • Grants$206%
  • Food & beverage$27887%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$318 in reported general payments places this provider in the 20th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York

Medicare billing

Part B allowed, 2024
$168,852
Medicare patients
458
Services billed
4,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin40$101,259
LinzessLinaclotide78$79,471
Mesalamine62$37,085
MotegrityPrucalopride Succinate25$14,061
Omeprazole530$7,439
Budesonide EcBudesonide18$6,150
Ursodiol15$4,505
Lansoprazole44$3,562
Famotidine200$3,090
CholestyramineCholestyramine (With Sugar)27$2,146
Lubiprostone17$1,897
Pantoprazole Sodium143$1,741
Dicyclomine Hcl54$1,139
Rabeprazole Sodium14$830
Esomeprazole Magnesium24$628

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$22$101,25940 claims
AbbVieLinzess$91$79,47178 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$25$14,06125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,682 gastroenterology providers in New York.

Other gastroenterology in Albany

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →